These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27184535)

  • 1. Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study.
    Gupta AA; Lee Chong A; Deveault C; Traubici J; Maloney AM; Knight S; Lorenzo A; Allen L
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):599-603. PubMed ID: 27184535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy.
    Elchuri SV; Patterson BC; Brown M; Bedient C; Record E; Wasilewski-Masker K; Mertens AC; Meacham LR
    J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):393-9. PubMed ID: 26924632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.
    Drechsel KCE; Broer SL; Stoutjesdijk FS; van Dulmen-den Broeder E; Beishuizen A; Wallace WH; Körholz D; Mauz-Körholz C; Hasenclever D; Cepelova M; Uyttebroeck A; Ronceray L; Twisk JWR; Kaspers GJL; Veening MA
    Hum Reprod; 2024 Aug; 39(8):1701-1711. PubMed ID: 38794915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
    Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
    Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
    van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
    Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer.
    Charpentier AM; Chong AL; Gingras-Hill G; Ahmed S; Cigsar C; Gupta AA; Greenblatt E; Hodgson DC
    J Cancer Surviv; 2014 Dec; 8(4):548-54. PubMed ID: 24810980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide.
    D'Avila ÂM; Biolchi V; Capp E; Corleta Hv
    J Ovarian Res; 2015 Dec; 8():82. PubMed ID: 26667243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
    Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
    Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC; Chan PT; To CH
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute onset of ovarian dysfunction in young females after start of cancer treatment.
    Mörse H; Elfving M; Lindgren A; Wölner-Hanssen P; Andersen CY; Øra I
    Pediatr Blood Cancer; 2013 Apr; 60(4):676-81. PubMed ID: 23015461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
    Dillon KE; Sammel MD; Prewitt M; Ginsberg JP; Walker D; Mersereau JE; Gosiengfiao Y; Gracia CR
    Fertil Steril; 2013 Feb; 99(2):477-83. PubMed ID: 23084267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.
    Lunsford AJ; Whelan K; McCormick K; McLaren JF
    Fertil Steril; 2014 Jan; 101(1):227-31. PubMed ID: 24083876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity.
    Ben-Aharon I; Granot T; Meizner I; Hasky N; Tobar A; Rizel S; Yerushalmi R; Ben-Haroush A; Fisch B; Stemmer SM
    Oncologist; 2015 Sep; 20(9):985-91. PubMed ID: 26099742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.